This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New RA Data Could Be Magic Pill for Rigel

Rigel Pharmaceuticals (RIGL) will release new clinical data next month on an experimental pill for rheumatoid arthritis that could alleviate concerns about the drug's safety and help the company sign a lucrative partnership deal later this year.

The Rigel drug, known as R788, is one of two oral medicines in mid- and late-stage clinical trials as a treatment for rheumatoid arthritis (RA), a progressive disease in which a patient's immune system attacks the bones and cartilage in the body's joints.

The current RA treatment market totals about $14 billion in sales worldwide, with the bulk of that coming from a class of injectable drugs known as "TNF-alpha inhibitors."

Rigel and Pfizer (PFE) are locked in a race to develop the first oral pill for RA that could compete with, and perhaps even supplant, the currently dominant TNF-alpha inhibitor drugs -- mainly Johnson & Johnson's (JNJ) Remicade; Enbrel, which is sold by Amgen (AMGN) and Wyeth (WYE); and Abbott Labs' (ABT) Humira.

Rigel, a small drugmaker based in South San Francisco, is conducting two phase II studies of R788 that have enrolled a total of about 650 patients with RA. The company expects to release the first results from these studies in July, followed by another data release in August.

Rigel shares have already begun moving higher as investors anticipate the new R788 data. Rigel shares trading at $8 in late May closed Friday at $11.89. The stock was up 2.7% to $12.21 in recent trading.

A previous and smaller phase II study of R788 released last year showed the drug to be effective at alleviating the pain and joint inflammation suffered by RA patients, but the study was too small to adequately assess R788's safety. RA is a chronic disease requiring patients to take drugs for the rest of their lives, so long-term safety is critical.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs